Fennec Pharmaceuticals Completes Full Debt Redemption
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) has successfully announced a significant financial milestone by repurchasing and redeeming all of its outstanding convertible notes. This marked a pivotal moment for the company as it moves towards enhancing its financial health and furthering its mission within the specialty pharmaceutical sector.
Details of the Debt Redemption
The total repurchase and redemption cost for the notes was approximately $21.7 million. This amount includes $19.5 million in principal, alongside accrued interest and a redemption fee. Originally, these notes carried a varying interest rate, which would have matured, but through strategic maneuvers involving an underwritten public offering and a private placement, the company was able to clear its outstanding debt.
Corporate Background of Fennec Pharmaceuticals
Founded on the principle of addressing ototoxicity related to chemotherapy, Fennec Pharmaceuticals is dedicated to introducing innovative treatments for patients facing the challenges of cancer therapies, particularly those receiving cisplatin-based chemotherapy. The launch of their key product, PEDMARK®, aims to mitigate the adverse effects associated with traditional cancer treatments, representing a critical breakthrough in patient care.
Regulatory Achievements and Commercialization
PEDMARK® received FDA approval in the United States in 2022, followed closely by approvals in Europe and the United Kingdom in the subsequent years. This positive regulatory progression highlights the commitment of Fennec Pharmaceuticals to not only develop but also successfully bring to market treatments that can significantly alter patient outcomes in cancer therapy.
Licensing Agreements and Market Expansion
In early 2024, Fennec secured an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI® in markets across Europe, the U.K., Australia, and New Zealand. This agreement is set to bolster Fennec's position in these vital regions while ensuring better accessibility for patients in need.
Pharmaceutical Innovations Ahead
Fennec Pharmaceuticals continues to drive innovation in the field with ongoing research aimed at expanding its product line and enhancing existing treatments. With their commitment to patient safety and efficacy, Fennec is positioned to play a crucial role in the future of oncology therapeutics.
Company Contact Information
For inquiries regarding investments or corporate affairs, Fennec Pharmaceuticals can be reached through their Chief Financial Officer, Robert Andrade, at +1 919-246-5299. For media-related questions, Lindsay Rocco of Elixir Health Public Relations is available at +1 862-596-1304 or via email.
Frequently Asked Questions
What is the significance of the debt redemption for Fennec Pharmaceuticals?
This redemption clears all outstanding debt, allowing Fennec more flexibility to invest in its business and future projects.
When did Fennec Pharmaceuticals receive regulatory approvals for its key product?
PEDMARK® received FDA approval in September 2022, followed by approvals from the European Commission and the U.K. in 2023.
What are Fennec Pharmaceuticals' main focuses?
The company specializes in treatments aimed at preventing ototoxicity in cancer patients undergoing cisplatin-based chemotherapy.
Who is responsible for commercialization in Europe?
Norgine Pharmaceuticals Ltd. has been granted exclusive rights for the commercialization of Fennec's products in various European markets.
How can investors reach Fennec Pharmaceuticals?
Investors can contact the CFO, Robert Andrade, at +1 919-246-5299 for more information regarding the company.
